BioLineRx Initiated Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia. BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death
BioLineRx Presented Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040 at European Hematology Association Conference. BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection. Graft derived from BL-8040 treatment shows unique cell composition.
BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany
"BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML - Data strongly suggest BL-8040 has potent anti-leukemic activity in combination with Ara-C in AML "-
"BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions Efficacy and safety study, in collaboration with MD Anderson Cancer Center, will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016"
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation.
BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia . Data also identify a potential biomarker for future selection of BL-8040-responsive AML patients
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx’s BL-8040 in combination with Atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of [...]
Tel Aviv, Israel, September 20, 2016 - BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy [...]
